A small phase II trial assessing FXI inhibition with a monoclonal antibody, gruticibart (previously known as AB023), for the prevention of catheter-associated thrombosis in patients with cancer undergoing central line placement, has also been recently published [43]. This evidence concerns the gene F11 and cancer.